The identification of activating mutations in mTOR that explain an exceptional response in a patient with bladder cancer is the latest example of mechanistic insights that can be gleaned from analyzing exceptional responders in otherwise failed trials. The NCI plans to sequence 100 such exceptional responders to help identify other cancer-related mutations that could predict drug response.